DONG JIANG¹, ZHI QI³, ZHIYING XU^2,*, YIRAN LI^1,*

Oncology Research, Vol.33, No.3, pp. 709-722, 2025, DOI:10.32604/or.2024.050125 - 28 February 2025

Abstract Background: Hepatocellular carcinoma (HCC) is a prevalent liver malignancy. This study examined the roles of transforming growth factor beta (TGF-β) and cytochrome b5 domain containing 2 (CYB5D2) in HCC etiology and their prognostic biomarker potential. Methods: Key modules and prognostic genes were identified by analyzing the GSE101685 dataset by weighted gene co-expression network analysis (WGCNA) and Least absolute shrinkage and selection operator (LASSO) Cox regression. The expression levels of CYB5D2 and TGF-β in HCC cell lines were quantified using Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting (WB) assays. Effects of CYB5D2 overexpression on cell proliferation,… More >

KE TIAN¹, ZHIPENG LI², XIANGYU ZHAI^2,3, HUAXIN ZHOU², HUI YAO^1,*

Oncology Research, Vol.33, No.3, pp. 617-630, 2025, DOI:10.32604/or.2024.049772 - 28 February 2025

Abstract Background: Primary liver cancer poses a significant global health burden, with projections indicating a surpassing of one million cases by 2025. Cuproptosis, a copper-dependent mechanism of cell death, plays a crucial role in the pathogenesis, progression, and prognosis of various cancers, including hepatocellular carcinoma (HCC). Purpose: This study aimed to develop a prognostic model for HCC based on cuproptosis-related genes, utilizing clinical data and gene expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Materials and Methods: Clinical features and gene expression data of HCC patients were collected from publicly available More >

GAMALELDIN I. HARISA^1,*, RIYAD F. ALZHRANI¹, ABDULRAHMAN A. ALLUHAIDAN¹, SULTAN M. ALAMRI¹, AHMED H. BAKHEIT², HANADI H. ASIRI², SABRY M. ATTIA³

Oncology Research, Vol.33, No.2, pp. 477-492, 2025, DOI:10.32604/or.2024.053337 - 16 January 2025

Abstract Background: Hepatocellular carcinoma (HCC) is a health problem due to multi-drug resistance (MDR). Codelivery of multiple oncotherapy in one cargo as chimeric cancer therapy (CCT) is suggested as a solution for MDR. This study aims to engineer chitosan-coated nanostructure lipid carriers (NLCs) loaded with gefitinib (GF) and simvastatin (SV) as CCT for HCC. Methods: Both GF and SV-loaded nanostructure lipids carriers (GFSVNLC) and chitosan-capped GF and SV-loaded nanostructure lipids carriers (CGFSVNLC) formulations were assembled by top-down techniques. Moreover, particle size (PS), zeta potential (ZP), and polydispersity index (PDI) were measured by Zetasizer. The biosafety of… More > Graphic Abstract

SHUO YU, MIN WANG, XU LI, XINGJUN GUO, RENYI QIN^*

Oncology Research, Vol.33, No.2, pp. 369-380, 2025, DOI:10.32604/or.2024.046774 - 16 January 2025

Abstract Background: Circular RNAs (circRNAs) play a pivotal role in the development and advancement of various cancer types. However, the involvement of circ-PAN3 in hepatocellular carcinoma (HCC) is not well understood. To shed light on this, we conducted a comprehensive study through biochemistry, cell biology, molecular biology, and bioinformatics techniques to investigate the role of circ-PAN3 and its associated pathway in the progression of HCC. Methods: Cell Counting Kit-8 (CCK-8) assay and colony formation assay were utilized to evaluate cell proliferation; Quantitative real-time PCR (RT-qPCR) and Western blot were adopted for assessing mRNA and protein expression;… More >

HAIYING PANG^1,#, FENGBO WU^1,#, YU ZHANG¹, NAN ZHANG², CHUNTING WANG¹, QIU LI¹, GU HE^1,*, PENG ZHANG^3,*

Oncology Research, Vol.33, No.2, pp. 443-464, 2025, DOI:10.32604/or.2024.043948 - 16 January 2025

Abstract Background: EMP2 is a tumor-associated membrane protein belonging to the GAS-3/PMP22 gene family. EMP2 expression demonstrates significant tissue specificity and heterogeneity in various human tissues and tumor tissues, where it may play a role in either promoting or inhibiting tumor growth. This study aimed to investigate the expression level, biological functions, and molecular mechanisms of EMP2 in liver cancer. Methods: we analyzed the mRNA expression levels of EMPs family genes in hepatocellular carcinoma (HCC) tissues and normal liver tissues based on the TCGA database and immunohistochemical analysis of tissue microarrays. Subsequently, we constructed HCC cell… More > Graphic Abstract

YUEZHOU ZHANG^1,#, ZHAO ZHANG^2,#, JINXIN DONG¹, CHANGAN LIU^1,*

Oncology Research, Vol.33, No.1, pp. 83-102, 2025, DOI:10.32604/or.2024.055866 - 20 December 2024

Abstract Background: Aberrant expression of RNA-binding proteins (RBPs) has been linked to a variety of diseases, including hematological disorders, cardiovascular diseases, and multiple types of cancer. Heterogeneous nuclear ribonucleoprotein C (HNRNPC), a member belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family, plays a pivotal role in nucleic acid metabolism. Previous studies have underscored the significance of HNRNPC in tumorigenesis; however, its specific role in malignant tumor progression remains inadequately characterized. Methods: We leveraged publicly available databases, including The Cancer Genome Atlas (TCGA), to explore the potential involvement of HNRNPC across various cancers. Additionally, we performed experimental… More > Graphic Abstract

NASSER MULLA^1,*, YOUSEF KATIB², ASIM M. ALMUGHAMSI³, DUAA S. ALKHAYAT¹, MOHAMED MOSAAD^1,4, SAMIR T. ALFOTIH⁵, RAWAN ALAOFI⁶

Oncology Research, Vol.33, No.1, pp. 149-160, 2025, DOI:10.32604/or.2024.050903 - 20 December 2024

Abstract Background: Hepatocellular carcinoma (HCC) is the most common cause of cancer-related death in Saudi Arabia. Our study aimed to investigate the patterns of HCC and the effect of TNM staging, Alfa-fetoprotein (AFP), and Child-Turcotte Pugh (CTP) on patients’ overall survival (OS). Methods: A retrospective analysis was conducted on 43 HCC patients at a single oncology center in Saudi Arabia from 2015 to 2020. All patients had to fulfill one of the following criteria: (a) a liver lesion reported as definitive HCC on dynamic imaging and/or (b) a biopsy-confirmed diagnosis. Results: The mean patient age of all… More >

ATIEH POURBAGHERI-SIGAROODI¹, MAJID MOMENY², NIMA REZAEI^3,4,5, FATEMEH FALLAH^1,*, DAVOOD BASHASH^6,*

BIOCELL, Vol.48, No.12, pp. 1781-1804, 2024, DOI:10.32604/biocell.2024.055848 - 30 December 2024

Abstract Background: Despite progress in therapeutic strategies, treatment failure in hepatocellular carcinoma (HCC) remains a major challenge, resulting in low survival rates. The presence of bacteria and the host’s immune response to bacteria can influence the pathogenesis and progression of HCC. We developed a risk model based on bacterial response-related genes (BRGs) using gene sets from molecular signature databases to identify new markers for predicting HCC outcomes and categorizing patients into different risk groups. Methods: The data from the Cancer Genome Atlas (TCGA) portal was retrieved, and differentially expressed BRGs were identified. Uni- and multivariate Cox… More >

SAM SON¹, AKSHAAR BRAHMBHATT¹, KEN ZHAO¹, BRETT MARINELLI¹, JAMES HARDING², WILLIAM JARNAGIN³, GHASSAN K. ABOU-ALFA², HOOMAN YARMOHAMMADI^1,*

Oncology Research, Vol.32, No.12, pp. 1831-1836, 2024, DOI:10.32604/or.2024.052985 - 13 November 2024

Abstract Background: This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma (FLC) treated with liver-directed therapies (LDT). Methods: In this single-center retrospective study, all patients diagnosed with FLC who underwent LDT were identified. Between July 2012 and July 2023, six patients were identified. One patient was excluded due to bleeding. Demographic and clinical parameters were recorded. Complications within 30 days of the LDT were evaluated. Radiological treatment responses at 1, 6, and 12 months were assessed per mRECIST. Results: A total of five patients, which included three females and two males, were reviewed.… More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1829-1829, 2024, DOI:10.32604/or.2024.056904 - 16 October 2024

Abstract This article has no abstract. More >